326 related articles for article (PubMed ID: 9055298)
1. Comparison of intrathecally administered urokinase, tissue-type plasminogen activator, and combination of urokinase and lysine-plasminogen for clot lysis after experimental subarachnoid hemorrhage in dogs.
Kajimoto Y; Ohta T; Kuroiwa T
Neurosurgery; 1997 Mar; 40(3):572-7. PubMed ID: 9055298
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of Lys- and mini-plasminogen on clot lysis induced by recombinant urokinase and recombinant pro-urokinase in a canine thrombosis model.
Burke SE; Davidson DJ; Lubbers NL; Reininger IM; Henkin J
Thromb Res; 1996 Sep; 83(6):421-31. PubMed ID: 8885137
[TBL] [Abstract][Full Text] [Related]
3. Vasospasm prevention with postoperative intrathecal thrombolytic therapy: a retrospective comparison of urokinase, tissue plasminogen activator, and cisternal drainage alone.
Usui M; Saito N; Hoya K; Todo T
Neurosurgery; 1994 Feb; 34(2):235-44; discussion 244-5. PubMed ID: 8177383
[TBL] [Abstract][Full Text] [Related]
4. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
Watahiki Y; Scully MF; Ellis V; Kakkar VV
Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
[TBL] [Abstract][Full Text] [Related]
5. The beneficial effect of lys-plasminogen upon the thrombolytic efficacy of urokinase in a dog model of peripheral arterial thrombosis.
Badylak SF; Voytik SL; Henkin J; Burke S; Sasahara AA; Simmons A
Haemostasis; 1991; 21(5):278-85. PubMed ID: 1806456
[TBL] [Abstract][Full Text] [Related]
6. Lysis of intraventricular blood clot with urokinase in a canine model: Part 3. Effects of intraventricular urokinase on clot lysis and posthemorrhagic hydrocephalus.
Pang D; Sclabassi RJ; Horton JA
Neurosurgery; 1986 Oct; 19(4):553-72. PubMed ID: 3491340
[TBL] [Abstract][Full Text] [Related]
7. Comparison of intrathecal administration of urokinase and tissue plasminogen activator on subarachnoid clot and chronic vasospasm in a primate model.
Hariton GB; Findlay JM; Weir BK; Kasuya H; Grace MG; Mielke BW
Neurosurgery; 1993 Oct; 33(4):691-6; discussion 696-7. PubMed ID: 8232810
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
Gurewich V; Pannell R
Thromb Res; 1986 Oct; 44(2):217-28. PubMed ID: 3097872
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of fibrinolytic properties of Alteplase, Tenecteplase and Urokinase in an in vitro clot model of intracerebral haemorrhage.
Keric N; Döbel M; Krenzlin H; Kurz E; Tanyildizi Y; Heimann A; König J; Kempski O; Ringel F; Masomi-Bornwasser J
J Stroke Cerebrovasc Dis; 2020 Sep; 29(9):105073. PubMed ID: 32807475
[TBL] [Abstract][Full Text] [Related]
10. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
Pannell R; Black J; Gurewich V
J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of urokinase-induced thrombolysis in a biphasic in vitro system.
Iga Y; Stella SR; Chandler AB
Haemostasis; 1985; 15(3):189-97. PubMed ID: 4029755
[TBL] [Abstract][Full Text] [Related]
12. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.
Lijnen HR; De Wreede K; Demarsin E; Collen D
Thromb Haemost; 1984 Aug; 52(1):31-3. PubMed ID: 6495261
[TBL] [Abstract][Full Text] [Related]
13. Fibrinolytic mechanism, biochemistry, and preclinical pharmacology of recombinant prourokinase.
Credo RB; Burke SE
J Vasc Interv Radiol; 1995; 6(6 Pt 2 Suppl):8S-18S. PubMed ID: 8770836
[TBL] [Abstract][Full Text] [Related]
14. Prourokinase mutant that induces highly effective clot lysis without interfering with hemostasis.
Liu JN; Liu JX; Liu Bf BF; Sun Z; Zuo JL; Zhang Px PX; Zhang J; Chen Yh YH; Gurewich V
Circ Res; 2002 Apr; 90(7):757-63. PubMed ID: 11964367
[TBL] [Abstract][Full Text] [Related]
15. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
Gurewich V; Pannell R
Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
[No Abstract] [Full Text] [Related]
16. Impaired clot lysis by rt-PA catalyzed mini-plasminogen activation.
Duboscq C; Genoud V; Parborell MF; Kordich LC
Thromb Res; 1997 Jun; 86(6):505-13. PubMed ID: 9219330
[TBL] [Abstract][Full Text] [Related]
17. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI.
Mutch NJ; Moore NR; Wang E; Booth NA
J Thromb Haemost; 2003 Sep; 1(9):2000-7. PubMed ID: 12941043
[TBL] [Abstract][Full Text] [Related]
18. Differences in the activation rates of plasminogen by tissue plasminogen activator and urokinase.
Takada A; Shizume K; Cho M; Takada Y
Thromb Res; 1987 Feb; 45(4):371-81. PubMed ID: 2437668
[TBL] [Abstract][Full Text] [Related]
19. Review of studies with plasminogen concentrates and proposals for further therapeutic strategies with plasminogen concentrates.
Anderle K; Fröhlich A
Haemostasis; 1988; 18 Suppl 1():165-75. PubMed ID: 3280422
[TBL] [Abstract][Full Text] [Related]
20. Disintegration and reorganization of fibrin networks during tissue-type plasminogen activator-induced clot lysis.
Meh DA; Mosesson MW; DiOrio JP; Siebenlist KR; Hernandez I; Amrani DL; Stojanovich L
Blood Coagul Fibrinolysis; 2001 Dec; 12(8):627-37. PubMed ID: 11734662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
